Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab
The combination of DEB-TACE, lenvatinib, and camrelizumab demonstrated efficacy in a patient with advanced HCC and lung metastases. These findings suggest that integrating MKIs and ICIs may represent a potential treatment approach for select advanced HCC cases, warranting further validation in larger studies.
Authors
- Baiguo Xu (ORCID: https://orcid.org/0000-0002-0269-5155)
- Zhongsong Gao
- Cui Yufeng
- Qing Ye (ORCID: https://orcid.org/0009-0004-5439-1892)
- Ning Wang (ORCID: https://orcid.org/0000-0002-6450-0421)
- Huiling Xiang (ORCID: https://orcid.org/0000-0001-5734-4080)
Institutions
- Tianjin Third Central Hospital (CN)
- Tianjin Infectious Diseases Hospital (CN)
- Cell Technology (China) (HK)
- Tianjin Central Hospital of Gynecology Obstetrics (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1549675
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32